Distinction and phasing of lung cancer and prognosis
The stratification, diagnosis and treatment of lung cancer, which is a common malignant tumour of the respiratory system, let’s look at the stratification and stratification of lung cancer. Lung cancer can be classified according to the anatomical part of the tumour, and can be classified into surrounding lung cancer and central lung cancer, with the following breakdown: 1. Peripheral lung cancer, which refers to the existence of a single spherical or contour nostrils around the pulmonary tissue, usually in pulmonary cancer of pulmonary bubbles and bronchial tubes below the bronchial trachea, mostly gland cancer. 2. Central lung cancer, which is common in the pulmonary bronchial or bronchial cavity around the pulmonary door, is mostly pulmonary carcinoma and small cell lung cancer. Lung cancer is classified according to specific pathological types and can be classified as small cell lung cancer and non-small cell lung cancer. Carcinomas of small-cell lung cancer are rounded or scaffolded, smaller in size and small in cell plasma, but are growing more rapidly and often more malignantly, and small-cell lung cancer is typically divided into small lungs of limited duration and extended small lungs of limited duration, i.e. tumours on one side of the lung or near lymphal knots, with a broad period of time when the cancer cell has been transferred to a double lung or even to organs other than the lung. Non-small cell lung cancer is divided into one, two, three and four periods. In the early stages of lung cancer, when the lung door and lymphocytes are not transferred, the tumors are usually small, and in the medium term, the tumor is usually greater than 5 cm, and when the cell moves further to the lymphoma, the lung cancer is in the third stage, i.e. the mid-term, and in the fourth stage, i.e. the most difficult to treat, if the tumor moves to the brain, bone, liver, etc., far away. There are also different treatments for tumours in different stages, with a first stage of lung cancer being treated mainly through surgical lymphomy and lymphomy, followed by post-operative complementary chemotherapy or target-to-pharmaceutical treatment, which can effectively prevent relapse and diversion. The second stage of lung cancer, mainly through pulmonary folic removal and lymphomy clean-up, followed by complementary chemotherapy, radiotherapy, target-to-pharmaceutical treatment, with a survival rate of around 80 per cent for three years after the operation, has had a better effect. The third stage of lung cancer is more advanced, and the treatment is less effective than the early stage of lung cancer, although most cannot be surgically removed, mainly by means of chemotherapy, radiotherapy, target-to-pharmaceutical treatment or, in recent years, by means of relatively new immunotherapy, the survival of patients has increased, mostly over two to three years. Patients of the fourth stage of lung cancer have no surgical indications, mainly using chemotherapy, radiotherapy, target-to-pharmaceutical treatment, etc., are among the last stage of lung cancer, which is usually ineffective, with a median life of less than one year. As a result, patients with lung cancer need early detection, early diagnosis, early diagnosis and, to the extent possible, improvement, rather than waiting for the most serious cases to delay treatment and survival.
The following groups at high risk of lung cancer include long-term smokers, second-hand smoke exposed persons, family history persons with lung cancer, occupationally exposed carcinogens such as asbestos, chronic lung diseases and long-term exposure to radon gas, recommended for regular low-dose CT screening. The prevention of lung cancer includes smoking cessation, the avoidance of second-hand smoke, the reduction of occupational exposure to carcinogens, the maintenance of indoor air cleanness, increased consumption of vegetables and vegetables, moderate exercise, periodic medical examinations and screening of high-risk groups.
Early detection and treatment can significantly improve survival rates.
